The Swedish Financial Supervisory Authority initiates investigation of Klaria Pharma’s handling and disclosing of inside information
The Swedish Financial Supervisory Authority (“SFSA”) has today notified Klaria Pharma Holding AB (“Klaria” or the “Company”) that the SFSA has decided to initiate an investigation of whether the Company has fulfilled its obligations pursuant to Article 17 and Article 18 of the EU Market Abuse Regulation (“MAR”) in connection with the rights issue of shares in the Company that ended on December 21, 2022. According to the notification received by the Company today it is further stated that the SFSA investigates if the authority should intervene against the Company in accordance with Chapter 2,